// Workers AI · dad joke modeWhat did Emestedastat say? It's a stat.
 | |
| Clinical data | |
|---|---|
| Other names | Xanamem; UE-2343; UE2343 |
| Routes of administration | Oral[1] |
| Drug class | 11β-Hydroxysteroid dehydrogenase type 1 inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C19H19N5O2S |
| Molar mass | 381.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome.[1][2] It is taken orally.[1]
The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol.[1][3][4][2]
Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical.[1] As of June 2026, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome.[1][2]
Clinical effectiveness for Alzheimer's disease has been mixed.[2] In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms.[5] In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.[5]
See also
[edit]References
[edit]- 1 2 3 4 5 6 "Emestedastat (UE-2343; Xanamem)". AdisInsight. 28 August 2024. Retrieved 9 October 2024.
- 1 2 3 4 Seckl J (January 2024). "11β-Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation". Journal of Internal Medicine. 295 (1): 20–37. doi:10.1111/joim.13741. PMID 37941106.
- ↑ Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G (March 2018). "Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention". Pharmacological Research. 129: 216–226. doi:10.1016/j.phrs.2017.11.021. PMID 29170097.
- ↑ Canet G, Hernandez C, Zussy C, Chevallier N, Desrumaux C, Givalois L (2019). "Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets". Frontiers in Aging Neuroscience. 11 269. doi:10.3389/fnagi.2019.00269. PMC 6776918. PMID 31611783.
- 1 2 Taylor JD, Rolan PE, Jaros MJ, Harrison JE, Ratcliffe SH, Berk M, et al. (July 2026). "A Phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder and cognitive impairment". Br J Psychiatry: 1–8. doi:10.1192/bjp.2026.10689. PMID 42464916.